SCHEMBL4931976

SCHEMBL4931976

Nc1ccc2c(c1)C(=O)N(C1CCC(=O)N(CCOC(=O)c3ccncc3)C1=O)C2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 6/20 0.36
MAPK1 P28482 2/20 0.36
GAA P10253 3/20 0.35
MEN1 O00255 3/20 0.35
CASP1 P29466 3/20 0.35
KMT2A Q03164 3/20 0.35
HSD17B10 Q99714 3/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.34
STAT3 P40763 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CASP7 P55210 2/20 0.34
ALOX15 P16050 1/20 0.34
MAP1LC3B Q9GZQ8 1/20 0.34
TSHR P16473 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19889418 0.93 DDB1 (0.36) DDB1CRBNSMN1; SMN2ALDH1A1MAPK1
SCHEMBL4936308 0.90 GAA (0.43) DDB1CRBNSMN1; SMN2ALDH1A1MAPK1
SCHEMBL4939030 0.89 SMN1; SMN2 (0.51) DDB1CRBNSMN1; SMN2ALDH1A1MAPK1
SCHEMBL18923264 0.85 L3MBTL1 (0.41) DDB1CRBNALDH1A1MAPK1GAA
SCHEMBL4939213 0.85 CRBN (0.47) DDB1CRBNALDH1A1MAPK1GAA
SCHEMBL4940283 0.85 DDB1 (0.43) DDB1CRBNSMN1; SMN2ALDH1A1GAA
Isonicotinic Acid SCHEMBL4931966 0.84 CRBN (0.43) DDB1CRBNALDH1A1GAAMEN1
SCHEMBL4937357 0.84 CRBN (0.48) DDB1CRBNALDH1A1GAAMEN1
SCHEMBL14297668 0.82 CRBN (0.44) DDB1CRBNALDH1A1MAPK1GAA
SCHEMBL4937872 0.81 CRBN (0.45) DDB1CRBNSMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-09-10 US disclosed
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-08-15 US disclosed
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-01-01 US disclosed
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2018-02-22 US disclosed
US-9669015-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-06-06 US disclosed
US-20150272940-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2015-10-01 US disclosed
US-9085563-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-07-21 US disclosed
US-20140179737-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-06-26 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
EP-1867649-B1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR TIAN JIN HEMAY BIO TECH CO LTD (CN) 2012-12-12 EP disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed
EP-1867649-A1 PIPERIDYL-2, 6-DIONE DERIVATIVES USED TO INHIBIT CELLS FROM RELEASING TUMOR NECROSIS FACTOR Tian Jin Hemay Bio-Tech Co., Ltd. (CN) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050025-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNFRSF9, TNFRSF1A, NGFR DDB1 2855/4885CRBN 949/4885SMN1; SMN2 4675/4885
US-10406147-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885SMN1; SMN2 4336/4885
US-10166222-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TNFRSF1A, TNFRSF9, NGFR DDB1 2770/4885CRBN 1007/4885SMN1; SMN2 4638/4885
US-20150272940-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885SMN1; SMN2 4336/4885
US-20190247383-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2373/4885CRBN 862/4885SMN1; SMN2 4400/4885
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885SMN1; SMN2 4336/4885
US-20140179737-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 DDB1 2336/4885CRBN 896/4885SMN1; SMN2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.